Marka loo eego natiijooyinka lagu dhawaaqay shirkii sannadlaha ah ee 2018 ASCO, CDK4 / 6 inhibitors pabociclib (Ibrance) iyo cetuximab (Erbitux) isku darka daaweynta platinum-u adkaysta iyo madax-bannaanida madax-bannaan ee soo noqnoqda / metastatic madaxa iyo nee.